InterVenn Biosciences
Gregory Czerwieniec is an accomplished scientist specializing in mass spectrometry and analytics, currently serving as Director of Mass Spectrometry and Analytics at Loxo@Lilly since July 2023 and holding the position of Senior Director for Biomarker Discovery at InterVenn Biosciences since July 2022. With extensive experience at Gilead Sciences as a Senior Research Scientist I since November 2016, Gregory has contributed to drug development through proteomic, lipidomic, and metabolomic applications. Previous roles include Staff Scientist at Nektar Therapeutics, Senior Scientist at KineMed, Inc., Senior Scientist at UCLA Proteomic Facility, and Postdoc Researcher at the Buck Institute for Age Research and Mount Sinai School of Medicine. Gregory holds a Ph.D. in Analytical Chemistry/Mass Spectrometry from the University of California, Davis.
This person is not in any teams
This person is not in any offices
InterVenn Biosciences
1 followers
InterVenn Biosciences utilizes a proprietary high-throughput glycoproteomic interrogation platform using artificial intelligence and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression.